CATCo Regulatory News (CAT)

13 Jun 2006 10:20

Cazenove13 June 2006 FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION Name of exempt principal trader Cazenove Company dealt in Cambridge Antibody Technology Group Class of relevant security to which the Ordinary 0.10pdealings being disclosed relate (Note 1) Date of dealing 12th June 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities Highest price paid Lowest price paidpurchased (Note 3) (Note 3) 9,286 £13.085p £13.085p Total number of securities Highest price received Lowest price receivedsold (Note 3) (Note 3) 9,286 £13.085p £13.08p (b) Derivatives transactions (other than options) Product name, Long/short Number of securities Price per unite.g. CFD (Note 4) (Note 5) (Note 3) (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Optionname,e.g selling, securities to price American, date moneypaid/call purchasing, which the European etc. receivedoption varying etc option per unit relates (Note (Note 3) 5) (ii) Exercising Product name, e.g. Number of securities Exercise price per unitcall option (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. .............................................................................. .............................................................................. Date of disclosure 13th June 2006 Contact name Barry Page Telephone number 0207 155 5907 Name of offeree/offeror with which connected AstraZeneca Plc Nature of connection (Note 6) Acting for AstraZeneca Plc Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange